Antibody-Drug Conjugates (ADCs) are a fundamental technology in modern tumor-targeted therapy with their ‘tripartite integrated design’ of ‘precision carrier - stable linker - potent payload’: The ...
In the past ten years, the number of antibody drug conjugate (ADC) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback